Regeneron and Sanofiâs Libtayo is granted marketing authorization by the European Commission for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma.
Original Article: Regeneron and Sanofi’s PD-1 inhibitor given go-ahead by EC